Puma Biotechnology, Inc. (PBYI): Operating Income
$37.30M
Year ended 2025-12-31
$30.44M
Trailing 12 months to 2026-06-30
+16.3%
3-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.30M | +20.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $30.97M | -5.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $32.64M | +37.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $23.72M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.29M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$30.40M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$39.05M | n/m | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | -$94.66M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$292.39M | n/m | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | -$276.60M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$240.28M | n/m | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | -$142.28M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$54.83M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$74.45M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$10.16M | n/a | 2014-03-03, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $37.30M | +20.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $47.90M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $23.50M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$159.31M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$151.17M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $67.57M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$50.17M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$386.00M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$166.90M | n/m |
Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗